<i>TP53</i> Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials

<i>TP53</i> Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials

(1) Background: locally resected high-grade sarcomas relapse in 40% of cases. There is no prognostic or predictive genomic marker for response to peri-operative chemotherapy. (2) Methods: MOSCATO and ProfiLER are pan-tumor prospective precision medicine trials for advanced tumors. Molecular analysis...

Full description

Bibliographic Details
Main Authors: Elise F. Nassif, Edouard Auclin, Rastilav Bahleda, Charles Honoré, Olivier Mir, Sarah Dumont, Benoite Mery, Khalil Hodroj, Mehdi Brahmi, Olivier Trédan, Isabelle Ray-Coquard, Jean-Yves Blay, Christophe Massard, Axel Le Cesne, Armelle Dufresne
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
TP53
biomarker
sarcoma
prognosis
anthracyclines
Online Access:https://www.mdpi.com/2072-6694/13/13/3362

Internet

https://www.mdpi.com/2072-6694/13/13/3362

Similar Items